文献速递头颈外科

p16阳性口咽癌影像检出结外扩展:RTOG 1016二次分析

Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该研究基于NRG RTOG 1016试验中586例p16阳性口咽癌且临床淋巴结阳性患者,由2名头颈影像专家评估CT模拟扫描中的影像检出结外扩展(iENE)。350例(60%)存在iENE,其5年总生存(79.2% vs 87.0%)和无进展生存(68.8% vs 80.4%)均劣于无iENE者;多因素分析显示iENE与更差OS(HR 1.63)和PFS(HR 1.78)独立相关。TNM9与TNM8临床淋巴结分期的C指数和AIC相近。

要点

  • p16阳性口咽癌临床淋巴结阳性患者中60%影像检出结外扩展。
  • iENE阳性者5年OS和PFS分别差7.8%和11.6%。
  • TNM9与TNM8临床淋巴结分期模型区分度相近。

核心结论

  • 在p16阳性口咽癌临床淋巴结阳性患者中,影像检出结外扩展与更差的总生存和无进展生存独立相关。
  • TNM9临床淋巴结分期将iENE阳性患者上调1个分层,其区分度与TNM8相近。

研究设计与样本

  • 预后研究,二次分析NRG RTOG 1016试验中2011至2014年入组的p16阳性口咽癌临床淋巴结阳性患者。
  • 共586例符合纳入标准,中位年龄58岁(范围33-83岁),男性534例(91.1%)。
  • 由2名头颈影像专家审阅CT模拟扫描记录iENE,中位随访4.2年(IQR 3.3-5.0年)。

主要发现

  • 350例(60%)存在iENE。
  • iENE阳性者5年OS为79.2%,无iENE者为87.0%,差异7.8%(95% CI 1.2%-14.4%)。
  • iENE阳性者5年PFS为68.8%,无iENE者为80.4%,差异11.6%(95% CI 4.1%-19.2%)。
  • 多因素分析中iENE与更差OS独立相关(HR 1.63;95% CI 1.04-2.56),与更差PFS独立相关(HR 1.78;95% CI 1.24-2.57)。
  • TNM8临床淋巴结分期C指数0.73(95% CI 0.68-0.78)、AIC 1109.34;TNM9 C指数0.72(95% CI 0.67-0.77)、AIC 1112.70。

关键数值与推荐

  • TNM9临床淋巴结分期将iENE阳性患者从TNM8临床N类别上调1个分层。
  • TNM9与TNM8临床淋巴结分期的C指数和AIC相近。

临床怎么用

  • 对p16阳性口咽癌临床淋巴结阳性患者,影像评估iENE有助于识别预后较差者。
  • TNM9临床淋巴结分期纳入iENE,可用于临床分期分层。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Imaging-detected extranodal extension (iENE) has been included in the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) protocol tumor-node-metastasis 9th edition staging system (TNM9) for human papillomavirus (HPV)-mediated (p16-positive) oropharyngeal cancer (HPV-positive OPC). OBJECTIVE: To confirm the new TNM9 staging system on a prospective dataset. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study included patients with HPV-positive OPC with clinically node-positive disease treated at 182 health care centers in the US and Canada and enrolled in the NRG Radiation Therapy Oncology Group (RTOG) 1016 trial between 2011 and 2014 were included. Deidentified images were reviewed between September and December 2021. Data were analyzed between May and September 2023. EXPOSURE: Computed tomography simulation scans were reviewed by 2 expert head and neck radiologists documenting the presence of iENE. MAIN OUTCOMES AND MEASURES: Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS). Cumulative incidence curves were generated for locoregional failure (LRF) and distant metastasis. Univariate (UVA) and multivariate analyses (MVA) were performed incorporating iENE with other known prognostic factors. The TNM9 clinical nodal schema incorporating iENE was compared with the previous TNM8. Model goodness of fit and comparison of models was done using Akaike information criterion (AIC) and Harrell concordance statistic (C index). RESULTS: Of the 987 patients enrolled in NRG RTOG 1016, 586 met inclusion criteria (median age, 58 years [range, 33-83 years]; 534 male [91.1%]), 350 (60%) of whom had iENE. Median (IQR) follow-up was 4.2 (3.3-5.0) years. Patients with iENE had inferior 5-year OS (79.2% vs 87.0%; difference, 7.8% [95% CI, 1.2%-14.4%]) and 5-year PFS (68.8% vs 80.4%; difference, 11.6% [95% CI, 4.1%-19.2%]) compared with those without iENE. On MVA, iENE was independently associated with inferior OS (HR, 1.63; 95% CI, 1.04-2.56) and PFS (HR, 1.78; 95% CI, 1.24-2.57). TNM9 and TNM8 clinical nodal schemas had similar performance in terms of C index and AIC (TNM8: C, 0.73 [95% CI, 0.68-0.78]; AIC = 1109.34 vs TNM9: C, 0.72 [95% CI, 0.67-0.77]; AIC = 1112.70). CONCLUSIONS AND RELEVANCE: This study showed that the updated TNM9 clinical nodal schema, in which patients with iENE-positive disease are upstaged 1 stratum from their TNM8 clinical N category, discriminates better than the TNM8 category between patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01302834.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Fleming CW, Reddy CA, Stock S, et al. Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42658511. doi:10.1001/jamaoto.2026.0932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。